SCH 527123

Description	in vitro: Sch527123 inhibits chemokine binding to CXCR1 and CXCR2 receptors in an insurmountable manner and is categorized as an allosteric antagonist. Sch527123 inhibits neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but has no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine. Sch527123 binding to CXCR1 and CXCR2 is both saturable and reversible. Sch527123 binds to CXCR1 with good affinity (Kd = 3.9 nM), the compound is CXCR2-selective (Kd = 0.049 nM) [1]. Sch527123 bound with high affinity to the CXCR2 receptors of mouse (Kd = 0.20 nM), rat (Kd = 0.20 nM), and cynomolgus monkey (Kd = 0.08 nM) and is a potent antagonist of CXCR2-mediated chemotaxis (IC50 ~3–6 nM). In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (Kd = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC50 ~1000 nM). in vivo: Oral treatment with Sch527123 blocks pulmonary neutrophilia (ED50 = 1.2 mg/kg) and goble
Pathways	GPCR/G Protein
Targets	CXCR

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.